What is heartburn worth?
- 1 March 2000
- journal article
- research article
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 15 (3) , 175-182
Abstract
OBJECTIVE: To determine the best treatment strategy for the management of patients presenting with symptoms consistent with uncomplicated heartburn. METHODS: We performed a cost-utility analysis of 4 alternatives: empirical proton pump inhibitor, empirical histamine2-receptor antagonist, and diagnostic strategies consisting of either esophagogastroduodenoscopy (EGD) or an upper gastrointestinal series before treatment. The time horizon of the model was 1 year. The base case analysis assumed a cohort of otherwise healthy 45-year-old individuals in a primary care practice. MAIN RESULTS: Empirical treatment with a proton pump inhibitor was projected to provide the greatest quality-adjusted survival for the cohort. Empirical treatment with a histamine2 receptor antagonist was projected to be the least costly of the alternatives. The marginal cost-effectiveness of using a proton pump inhibitor over a histamine2-receptor antagonist was approximately $10,400 per quality-adjusted life year (QALY) gained in the base case analysis and was less than $50,000 per QALY as long as the utility for heartburn was less than 0.95. Both diagnostic strategies were dominated by proton pump inhibitor alternative. CONCLUSIONS: Empirical treatment seems to be the optimal initial management strategy for patients with heartburn, but the choice between a proton pump inhibitor or histamine2-receptor antagonist depends on the impact of heartburn on quality of life.Keywords
This publication has 40 references indexed in Scilit:
- The effect of omeprazole (OME) 20 mg and 10 mg daily on heartburn in patients with endoscopy negative reflux disease (ENRD)Gastroenterology, 1995
- Treatment of erosive reflux esophagitis resistant to H2-receptor antagonist therapyDigestive Diseases and Sciences, 1995
- The symptom indexDigestive Diseases and Sciences, 1993
- Lansoprazole versus Omeprazole in Short-Term Treatment of Reflux Oesophagitis Results of a Scandinavian Multicentre TrialScandinavian Journal of Gastroenterology, 1993
- Prevention of Relapse of Reflux Esophagitis after Endoscopic Healing: The Efficacy and Safety of Omeprazole Compared with RanitidineScandinavian Journal of Gastroenterology, 1991
- Prevention of Relapse of Reflux Oesophagitis after Endoscopic Healing: The Efficacy and Safety of Omeprazole Compared with RanitidineDigestion, 1990
- Heartburn--the acid test.Gut, 1989
- Evaluation of Omeprazole in Reflux OesophagitisScandinavian Journal of Gastroenterology, 1989
- Omeprazole (40 mg) is superior to ranitidine in short-term treatment of ulcerative reflux esophagitisDigestive Diseases and Sciences, 1988
- Probabilistic Sensitivity Analysis Using Monte Carlo SimulationMedical Decision Making, 1985